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We agree that it is likely that our data underestimates the true C max and AUC, though there is no reason to believe that values would differ between groups. However, one factor that may delay the time at which C max occurs (T max ) is to take the drug with food, in particular with high-fat meals (5). Thus, it is recommended that isoniazid be given on an empty stomach. In our study, we were unable to adequately control or reliably measure the concomitant food intake of all the patients, and this fact may have influenced the final results. In this regard, another study is being undertaken with an aim to reliably control food intake with the drugs of patients, and at the same time, the pharmacokinetics of TB drugs will be measured at three time points: 2, 4, and 6 h after the drug intake. Larger studies like this one are required; using sparse population pharmacokinetic sampling schemes in different settings would be desirable, though these probably require a greater level of research infrastructure than is currently available in public clinics in Lima, Peru.
Regarding treatment outcome, in this subanalysis, we included only 41 drug-susceptible patients and excluded patients diagnosed with multidrug-resistant TB, patients who either abandoned treatment or did not properly complete treatment, and others who lacked a microbiologically confirmed diagnosis. However, we agree that our study was not designed to relate the treatment schedule strategy to treatment outcome and that larger studies with long-term follow-up are required to provide relevant data in this respect.
